Posted by Michael Wonder on 21 Sep 2022
Health Canada approves Takeda's Livtencity (maribavir) the first and only treatment for adults with post-transplant cytomegalovirus infection
20 September 2022 - Takeda Canada is pleased to announce that Health Canada has authorized (Notice of Compliance) Livtencity (maribavir) for the treatment of adults with post-transplant cytomegalovirus infection/disease who are refractory (with or without genotypic resistance) to one or more prior anti-viral therapies.
Compared to conventionally used anti-virals to treat post-transplant cytomegalovirus infection/disease, Livtencity offers twice the efficacy and more than 10 times less toxicity.
